Hsbc Holdings PLC Has $355,000 Stock Position in Fulcrum Therapeutics, Inc. (NASDAQ:FULC)

Hsbc Holdings PLC lifted its holdings in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 55.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 75,959 shares of the company’s stock after acquiring an additional 26,944 shares during the period. Hsbc Holdings PLC owned approximately 0.14% of Fulcrum Therapeutics worth $355,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. MetLife Investment Management LLC lifted its position in Fulcrum Therapeutics by 145.8% during the fourth quarter. MetLife Investment Management LLC now owns 40,107 shares of the company’s stock worth $189,000 after purchasing an additional 23,792 shares during the period. MYDA Advisors LLC acquired a new stake in shares of Fulcrum Therapeutics during the 4th quarter worth approximately $301,000. Altium Capital Management LLC acquired a new position in Fulcrum Therapeutics during the fourth quarter valued at approximately $526,000. Zacks Investment Management bought a new stake in Fulcrum Therapeutics during the fourth quarter worth $99,000. Finally, Mariner LLC acquired a new stake in shares of Fulcrum Therapeutics in the 4th quarter valued at $78,000. Institutional investors and hedge funds own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Up 6.7 %

Fulcrum Therapeutics stock opened at $5.41 on Friday. The firm has a fifty day simple moving average of $3.34 and a two-hundred day simple moving average of $3.68. Fulcrum Therapeutics, Inc. has a twelve month low of $2.32 and a twelve month high of $10.13. The company has a market capitalization of $292.03 million, a PE ratio of -17.45 and a beta of 2.29.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. As a group, equities analysts expect that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.63.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.